Welcome to our dedicated page for Relay Therapeutics news (Ticker: RLAY), a resource for investors and traders seeking the latest updates and insights on Relay Therapeutics stock.
Relay Therapeutics, Inc. develops clinical-stage small molecule precision medicines for cancer and genetic disease. The company uses its Dynamo® platform, which combines computational and experimental approaches to drug protein targets that have been intractable or inadequately addressed.
Recurring RLAY news centers on zovegalisib (RLY-2608), a mutant-selective PI3Kα inhibitor studied in HR+/HER2- metastatic breast cancer and PI3Kα-driven vascular anomalies. Company updates also cover pipeline programs for NRAS-driven solid tumors and Fabry disease, clinical and regulatory data presentations, operating results, capital-structure matters, license or collaboration agreements, and governance developments.
Relay Therapeutics (Nasdaq: RLAY) recently closed its initial public offering, selling 23 million shares at $20.00 each, generating $460 million in gross proceeds. This includes the full exercise of the underwriters’ option for an additional 3 million shares. The shares began trading on July 16, 2020. The offering was managed by J.P. Morgan, Goldman Sachs, Cowen, and Guggenheim Securities. Relay Therapeutics focuses on precision medicine and enhancing small molecule therapeutic discovery in oncology using its innovative Dynamo platform.
Relay Therapeutics priced its initial public offering of 20 million shares at $20.00 each, aiming for gross proceeds of $400 million. The offering is set to close on July 20, 2020, pending customary conditions. J.P. Morgan, Goldman Sachs, Cowen, and Guggenheim Securities serve as joint book-running managers. Trading is scheduled to commence on July 16, 2020, on Nasdaq under the symbol 'RLAY'. The company's innovative approach focuses on precision medicine and the dynamics of protein motion, targeting previously difficult protein drug targets in oncology.